Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial

Abstract Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in the EMPA-REG OUTCOME® trial. We investigated whether the benefit of empagliflozin was observed across the spect...

Full description

Saved in:
Bibliographic Details
Published in:European heart journal 2018-02, Vol.39 (5), p.363-370
Main Authors: Fitchett, David, Butler, Javed, van de Borne, Philippe, Zinman, Bernard, Lachin, John M, Wanner, Christoph, Woerle, Hans J, Hantel, Stefan, George, Jyothis T, Johansen, Odd Erik, Inzucchi, Silvio E
Format: Article
Language:English
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Aims Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in the EMPA-REG OUTCOME® trial. We investigated whether the benefit of empagliflozin was observed across the spectrum of HF risk. Methods and results Seven thousand and twenty patients with T2D (HbA1c 7–10% and eGFR > 30 mL/min/1.73 m2) were treated with empagliflozin 10 or 25 mg, or placebo once daily and followed for median 3.1 years. In patients without HF at baseline (89.9%), we derived the 5-year risk for incident HF using the 9-variable Health ABC HF Risk score [classified as low-to-average (
ISSN:0195-668X
1522-9645
DOI:10.1093/eurheartj/ehx511